Praxis Precision Medicines Inc Forecast, price target & analysts
Praxis Precision Medicines Inc Target price 2025 - Analyst rating & recommendation
Praxis Precision Medicines Inc Classifications & Recommendation:
Praxis Precision Medicines Inc Price Target
| Target Price | $265.71 |
| Price | $169.80 |
| Potential |
56.48%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Praxis Precision Medicines Inc 2026 .
The average Praxis Precision Medicines Inc target price is $265.71.
This is
56.48%
register free of charge
$463.05
172.70%
register free of charge
$65.65
61.34%
register free of charge
|
|
| A rating was issued by 20 analysts: 18 Analysts recommend Praxis Precision Medicines Inc to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Praxis Precision Medicines Inc stock has an average upside potential 2026 of
56.48%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 8.55 | 0.09 |
| 248.98% | 98.99% | |
| EBITDA Margin | -2,336.96% | -346,544.55% |
| 54.54% | 14,728.87% | |
| Net Margin | -2,138.25% | -335,609.30% |
| 57.51% | 15,595.54% |
16 Analysts have issued a sales forecast Praxis Precision Medicines Inc 2025 . The average Praxis Precision Medicines Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Praxis Precision Medicines Inc EBITDA forecast 2025. The average Praxis Precision Medicines Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Praxis Precision Medicines Inc Analysts have issued a net profit forecast 2025. The average Praxis Precision Medicines Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -10.21 | -13.68 |
| 45.37% | 33.99% | |
| P/E | negative | |
| EV/Sales | 46,100.68 |
16 Analysts have issued a Praxis Precision Medicines Inc forecast for earnings per share. The average Praxis Precision Medicines Inc EPS is
This results in the following potential growth metrics and future valuations:
Praxis Precision Medicines Inc...
Current Praxis Precision Medicines Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Nov 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 13 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Deutsche Bank |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Nov 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 13 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Oct 20 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Oct 17 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
